Background/aims: Intralesional steroid injections have been administered as prophylaxis for stenosis after esophageal endoscopic submucosal dissection. However, this method carries a risk of potential complications such as perforation because a fine needle is used to directly puncture the postoperative ulcer. We devised a new method of steroid intralesional infusion using a spray tube and evaluated its efficacy and safety.
Methods: Intralesional steroid infusion using a spray tube was performed on 27 patients who underwent endoscopic submucosal dissection for superficial esophageal cancer with three-quarters or more of the lumen circumference resected. The presence or absence of stenosis, complications, and the number of endoscopic balloon dilations (EBDs) performed were evaluated after treatment.
Results: Although stenosis was not observed in 22 of the 27 patients, five patients had stenosis and dysphagia requiring EBD. The stenosis in these five patients was relieved after four EBDs. No complications related to intralesional steroid infusion using the spray tube were observed.
Conclusion: Intralesional steroid infusion using a spray tube is a simple and safe technique that is adequately effective in preventing stenosis Clinical trial number (UMIN000037567).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329638 | PMC |
| http://dx.doi.org/10.5946/ce.2021.262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review.
Arch Dermatol Res
January 2025
Department of Dermatology, College of Medicine, The Ohio State University Wexner Medical Center, 540 Officenter Place, Columbus, OH, 43230, USA.
The use of immunotherapy is an emerging treatment option for advanced malignancies. Cutaneous adverse events following cancer immunotherapy are well-documented in the literature. The rarer cutaneous adverse effects are less characterized, including eruptive keratoacanthomas (KA).
View Article and Find Full Text PDFTreatment of facial reactive B-cell rich lymphoid proliferation with dapsone.
J Dermatol
January 2025
Department of Dermatology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Reactive B-cell rich lymphoid proliferation (rB-LP), once called pseudolymphoma, is a benign lymphoproliferative disorder, which is histologically characterized by dense dermal infiltrate forming reactive germinal centers with tingible body macrophages. The disease frequently involves the face, scalp, and ear lobes. Treatment includes topical or intralesional steroids, surgical resection, ultraviolet therapy, laser treatment, and radiation therapy.
View Article and Find Full Text PDFFrontal Fibrosing Alopecia Part II: Etiopathogenesis and Management.
J Am Acad Dermatol
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL.
Frontal Fibrosing Alopecia (FFA) poses a distinct dermatological challenge with epithelial-mesenchymal transition (EMT) at its core, driving follicular cell transformation and fibrotic changes. Genetic studies highlight significant associations, while environmental triggers, such as implicated cosmetic products (sunblock, personal hair care products, and moisturizers), introduce complexity. Managing FFA proves daunting due to its chronic and unpredictable nature.
View Article and Find Full Text PDFDifferential Expression of Proteins Involved in Skin Barrier Maintenance and Vitamin D Metabolism in Atopic Dermatitis: A Cross-Sectional, Exploratory Study.
Int J Mol Sci
December 2024
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
Atopic dermatitis (AD) is a chronic inflammatory skin disorder influenced by proteins involved in skin barrier maintenance and vitamin D metabolism. Using an intra-patient design, this study compared protein expression in intra-lesional (IL) and peri-lesional (PL) skin biopsies from AD patients and examined associations between protein levels, vitamin D status, and clinical features. Forty-four biopsies from twenty-two AD patients were analyzed using antibody microarrays targeting twelve proteins.
View Article and Find Full Text PDFFeatures, Treatments, and Therapeutic Outcomes of Peristomal versus Non-Peristomal Pyoderma Gangrenosum in 45 Patients with Inflammatory Bowel Disease: A Single-Institution Study, 2002 through 2021.
Skinmed
January 2025
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA.
Pyoderma gangrenosum (PG) is the second most common skin manifestation reported in patients with inflammatory bowel disease (IBD). We performed a single-institution, retrospective study to summarize the clinical features and examine effective treatment regimens and outcomes of PG in IBD patients. We identified 45 patients who presented to our institute between January 1, 2002 and December 31, 2021 with the following criteria: (1) diagnosed with an active PG (ICD9: 686.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!